Drug Profile
PF 489791
Alternative Names: PF-00489791; PF-0489791; PF-489791Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antihypertensives; Small molecules
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Diabetic nephropathies; Hypertension; Postherpetic neuralgia; Pulmonary hypertension; Raynaud's disease; Renal failure
Most Recent Events
- 04 May 2016 Discontinued - Phase-I for Diabetic nephropathies in Belgium (PO) (Pfizer pipeline, May 2016)
- 04 May 2016 Discontinued - Phase-II for Diabetic nephropathies in Canada, South Korea, United Kingdom, Hong Kong, USA, Mexico, Malaysia, South Africa, Poland, Sweden, Denmark, Slovakia, Australia, India, Serbia (PO) (Pfizer pipeline, May 2016)
- 17 Jun 2015 Phase-II development for Diabetic nephropathies is ongoing in World